BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Iovance Biotherapeutics Stock Rises on Regulatory Approval and Analyst Optimism
Iovance Biotherapeutics Stock Rises on Regulatory Approval and Analyst Optimism
13
1
BTCCSquare news:
Iovance Biotherapeutics (IOVA) shares gained nearly 6% during Tuesday's trading session, outperforming the broader market's 0.5% decline. The surge followed Health Canada's conditional approval of its cancer drug Amtagvi for advanced melanoma treatment—marking the company's first international regulatory success.
Analyst Joseph Pantginis of H.C. Wainwright maintained a buy rating with a $20 price target, reinforcing positive sentiment. The biotech firm plans to establish Canadian treatment centers in coming months while pursuing additional global approvals for its FDA-cleared cellular therapy.
By:
